Last Update: Aug 14, 2026 SEC-HOPE: A Multicenter Retrospective Cohort Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD ClinicalTrials.gov Identifier: [NCT07683065](https://clinicaltrials.gov/ct2/show/NCT07683065) Novartis Reference Number:CAIN457AES18 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \\\[PsA\\\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals. Condition Plaque Psoriasis, Metabolic Dysfunction-Associated Steatotic Liver Disease Overall Status Recruiting Number of Participants150 Start Date Jul 08, 2026 Completion Date Jan 15, 2027 Gender All Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: \* Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023. \* Patients aged ≥18 years at index date. \* Patients with no prior secukinumab exposure in available EMR history. \* Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA). \* Patients with documented administration per Summary of Product Characteristics dosing recommendations (SmPC). \* Patients with confirmed plaque psoriasis with or without PsA. \* Patients with at least one cardiometabolic risk factor. \* Patients with a confirmed MASLD diagnosis. \* Patients with baseline laboratory data available. Exclusion criteria: \* Patients with evidence of MASLD absence. \* Patients with malignant liver disease. \* Patients with a history of liver transplantation. \* Patients with alcohol use disorder. \* Patients with other chronic liver diseases. \* Patients with diseases or treatments which cause thrombocytopenia. \* Patients with decompensated cirrhosis. Other protocol-defined inclusion/exclusion criteria may apply. Spain #### Novartis Investigative Site Recruiting Badalona,Barcelona,08916,Spain #### Novartis Investigative Site Recruiting Madrid,28041,Spain #### Novartis Investigative Site Recruiting Málaga,29010,Spain #### Novartis Investigative Site Recruiting Barcelona,08035,Spain ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: